Table 4.
Distribution of antigen and haplotype frequencies with significant impact on outcome (progression-free and overall survival) among N = 94 patients with HPV-driven (HPV-DNA+ RNA+ or HPV-DNA+ p16+) head and neck squamous cell carcinoma with primary in the oropharynx (OPSCC; n = 57, 60.6%) or outside the oropharynx (other; n = 37, 39.4%).
| HLA s | Total | OPSCC | Other HNSCC | |||||
|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | OR (95% CI) | p-value † | |
| A1C | ||||||||
| Non-carrier | 29 | (30.9) | 18 | (31.6) | 11 | (29.7) | Ref. (0.346 –2.889) | 0.850 |
| Carrier | 65 | (69.1) | 39 | (68.4) | 26 | (70.3) | 0.917 (0.373 –2.253) | |
| B12C | ||||||||
| Non-carrier | 49 | (52.1) | 31 | (54.4) | 18 | (48.6) | Ref. (0.440 –2.274) | 0.586 |
| Carrier | 45 | (47.9) | 26 | (45.6) | 19 | (51.4) | 0.795 (0.347 –1.820) | |
| A11 | ||||||||
| Non-carrier | 84 | (89.4) | 54 | (94.7) | 30 | (81.1) | Ref. (0.532 –1.880) | 0.036 |
| Carrier | 10 | (10.6) | 3 | (5.3) | 7 | (18.9) | 0.238 (0.057 –0.989) | |
| B51 | ||||||||
| Non-carrier | 80 | (85.1) | 48 | (84.2) | 32 | (86.5) | Ref. (0.531 –1.882) | 0.762 |
| Carrier | 14 | (14.9) | 9 | (15.8) | 5 | (13.5) | 1.200 (0.368 –3.910) | |
| A1-B8 | ||||||||
| Non-carrier | 81 | (86.2) | 48 | (84.2) | 33 | (89.2) | Ref. (0.534 –1.872) | 0.495 |
| Carrier | 13 | (13.8) | 9 | (15.8) | 4 | (10.8) | 1.547 (0.439 –5.445) | |
| A3-B18 | ||||||||
| Non-carrier | 87 | (92.6) | 50 | (87.7) | 37 | (100.0) | Ref. (0.548 –1.824) | 0.027 |
| Carrier | 7 | (7.4) | 7 | (12.3) | 0 | – | 11.14 (0.617 –201.2) # | |
| DR15 | ||||||||
| Non-carrier | 69 | (73.4) | 44 | (77.2) | 25 | (67.6) | Ref. (0.499 –2.002) | 0.302 |
| Carrier | 25 | (26.6) | 13 | (22.8) | 12 | (32.4) | 0.616 (0.244 –1.553) | |
| DQB1 homozygosity | ||||||||
| Non-carrier or heterozygous | 85 | (90.4) | 52 | (91.2) | 33 | (89.2) | Ref. (0.540 –1.853) | 0.743 |
| DQB1 homozygous | 9 | (9.6) | 5 | (8.8) | 4 | (10.8) | 0.793 (0.199 –3.170) | |
| HLA risk groups | ||||||||
| Low risk | 18 | (19.1) | 12 | (21.1) | 6 | (16.2) | Ref. (0.250 –3.999) | 0.891 |
| Intermediate-low risk | 29 | (30.9) | 18 | (31.6) | 11 | (29.7) | 0.818 (0.238 –2.811) | |
| Intermediate-high risk | 34 | (36.2) | 19 | (33.3) | 15 | (40.5) | 0.633 (0.192 –2.084) | |
| High risk | 13 | (13.8) | 8 | (14.0) | 5 | (13.5) | 0.800 (0.181 –3.536) | |
| Clinical risk groups | ||||||||
| Low risk | 28 | (29.8) | 28 | (49.1) | 0 | – | Ref. (0.019 –52.16) # | < 0.001 |
| Intermediate-low risk | 25 | (26.6) | 1 | (1.8) | 24 | (64.9) | 0.001 (0.000 –0.023) | |
| Intermediate-high risk | 28 | (29.8) | 22 | (38.6) | 6 | (16.2) | 0.064 (0.003 –1.215) | |
| High risk | 13 | (13.8) | 6 | (10.5) | 7 | (18.9) | 0.015 (0.001 –0.302) | |
| PFS risk groups (HLA + clinical) | ||||||||
| Low risk | 15 | (16.0) | 14 | (24.6) | 1 | (2.7) | Ref. (0.057 –17.62) | 0.037 |
| Intermediate-low risk | 32 | (34.0) | 18 | (31.6) | 14 | (37.8) | 0.092 (0.011 –0.785) | |
| Intermediate-high risk | 32 | (34.0) | 18 | (31.6) | 14 | (37.8) | 0.092 (0.011 –0.785) | |
| High risk | 15 | (16.0) | 7 | (12.3) | 8 | (21.6) | 0.063 (0.006 –0.604) | |
† p-values from Pearson’s Chi-square (χ2) tests for contingency tables; # odds ratio corrected according to Cox by adding 1 to each cell preventing division by zero; significant p-values < 0.05 highlighted in bold.